Denosumab in men with non-metastatic castration-resistant prostate cancer (CRPC) and PSA doubling time (PSADT) ≤6 months - a post-hoc analysis of a randomised trial

被引：0
|
作者：
Wong, S. [1 ]
Miller, K. [2 ]
Smith, M. R. [3 ]
Dearnaley, D. [4 ]
Dogliott, L. [5 ]
Egerdie, B. [6 ]
Fizazi, K. [7 ]
Kueppers, F. [8 ]
Montes De Oca, L. [9 ]
Morote, J. [10 ]
Pavlik, I. [11 ,12 ]
Sieber, P. [13 ]
Tammel, T. J. [14 ]
Van Poppel, H. [15 ]
Wirth, M. [16 ]
Ye, Z. [17 ]
Braun, A. [17 ]
机构：
[1] Western Hosp, Footscray, Vic, Australia
[2] Charite, Berlin, Germany
[3] Massachusetts Gen Hosp Canc Ctr, Boston, MA USA
[4] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England
[5] Osped San Luigi Gonzaga, Orbassano, TO, Italy
[6] Urol Associates, Urol Med Res, Kitchener, ON, Canada
[7] Univ Paris Sud, Inst Gustave Roussy, Villejuif, France
[8] Canterbury Urol Res Trust, Christchurch, New Zealand
[9] Ctr Diagnost Urol, Buenos Aires, DF, Argentina
[10] Hosp Valle De Hebron, Barcelona, Spain
[11] Gen Teaching Hosp, Urol Clin, Prague, Czech Republic
[12] Fac Med 1, Prague, Czech Republic
[13] Urol Associates Lancaster, Lancaster, PA USA
[14] Tampere Univ Hosp, Tampere, Finland
[15] Univ Ziekenhuis Gasthuisberg, Louvain, Belgium
[16] Univ Klinikum Carl Gustav Carus, Dresden, Germany
[17] Amgen Inc, Thousand Oaks, CA 91320 USA
来源：
BJU INTERNATIONAL | 2013年 / 111卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
51
引用
收藏
页码：37 / 38
页数：2
相关论文
共 50 条
  • [41] Pain progression at initiation of cabazitaxel in metastatic castration-resistant prostate cancer (mCRPC) is associated with a poor prognosis: a post-hoc analysis of PROSELICA.
    Delanoy, Nicolas
    De Bono, Johann S.
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    Eisenberger, Mario A.
    Oudard, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [42] DAROLUTAMIDE SIGNIFICANTLY IMPROVES OVERALL SURVIVAL WITH A TOLERABLE SAFETY PROFILE IN MEN WITH NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
    Sutton, Jennifer
    Olivier, Kara
    Petrenciuc, Oana
    Sarapohja, Toni
    Smith, Matthew
    Shore, Neal
    ONCOLOGY NURSING FORUM, 2021, 48 (02)
  • [43] Clinical and Immunological Analysis of a Phase I Trial Evaluating MVA-BN®-PRO in patients with Non-metastatic Castration Resistant Prostate Cancer (CRPC)
    Legrand, Fatema A.
    McLeod, David
    Bilhartz, David
    Gittleman, Marc
    Adams, George
    Cochran, James
    Reiling, Richard
    Ruiz, Henry
    Karlin, Gary
    Owen, Rachel
    Nguyen, Anh-Tuan
    Hwang, Olivia
    Paranjpe, Gayatri
    Fernandez, Leilani
    Brand, Leslie
    Laus, Reiner
    Delcayre, Alain
    Godfrey, Wayne
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (08) : 900 - 901
  • [44] Treatment, healthcare resource utilization, and costs associated with non-metastatic and metastatic castration-resistant prostate cancer: A claims analysis.
    Valderrama, Adriana
    Tangirala, Krishna
    Babajanyan, Svetlana
    Appukkuttan, Sreevalsa
    Wen, Lonnie Kent
    Malacan, Jean
    Shore, Neal D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [45] First-Line Treatment After the Failure of Androgen Deprivation Therapy for Non-Metastatic, Castration-Resistant Prostate Cancer Men
    Zhu, Yuhong
    Yang, Gaojie
    Ding, Yangyang
    Wu, Lifen
    INTERNATIONAL JOURNAL OF PHARMACOLOGY, 2022, 18 (04) : 714 - 720
  • [46] Patient-reported outcomes following enzalutamide or placebo in men with non-metastatic, castration-resistant prostate cancer (PROSPER): a multicentre, randomised, double-blind, phase 3 trial
    Tombal, Bertrand
    Saad, Fred
    Penson, David
    Hussain, Maha
    Sternberg, Cora N.
    Morlock, Robert
    Ramaswatny, Krishnan
    Ivanescu, Cristina
    Attard, Gerhardt
    LANCET ONCOLOGY, 2019, 20 (04): : 556 - 569
  • [47] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC).
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [48] Pain Progression at Initiation of Cabazitaxel in Metastatic Castration-Resistant Prostate Cancer (mCRPC): A Post Hoc Analysis of the PROSELICA Study
    Delanoy, Nicolas
    Robbrecht, Debbie
    Eisenberger, Mario
    Sartor, Oliver
    de Wit, Ronald
    Mercier, Florence
    Geffriaud-Ricouard, Christine
    de Bono, Johann
    Oudard, Stephane
    CANCERS, 2021, 13 (06) : 1 - 13
  • [49] Effects of 6 months of abiraterone acetate (AA) on muscle and adipose mass in men with metastatic castration-resistant prostate cancer (mCRPC)
    Brondfield, Samuel Craig
    Weinberg, Vivian K.
    Koepfgen, Kathryn M.
    Molina, Arturo
    Ryan, Charles J.
    Small, Eric Jay
    Harzstark, Andrea Lynne
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (05)
  • [50] An interim analysis of non-interventional study of the epidemiology and natural history of non-metastatic castration-resistant prostate cancer in Russia
    Alekseev, B. Ya
    Nyushko, K. M.
    Gafanov, R. A.
    Kirichek, A. A.
    Anzhiganova, Yu, V
    Kopyltsov, E., I
    Sundui, Yu Yu
    Matveev, V. B.
    ONKOUROLOGIYA, 2020, 16 (03): : 90 - 101
12345